KRAS and lung adenocarcinoma: Furthermore, the in vivo targeting of IMCs by the CCR1 inhibitor effectively suppressed tumour progression in vivo (Fig4) in a similar way to the targeting of TAMs in the oncogenic KRAS-induced lung adenocarcinoma model (Cortez-Retamozo et al, 2012).